Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;8(1):5-17.
doi: 10.1007/s40123-019-0164-z. Epub 2019 Jan 29.

Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment

Panagiotis Georgoudis  1 , Francesco Sabatino  2 , Nora Szentmary  3   4 , Sotiria Palioura  5 , Eszter Fodor  4 , Samer Hamada  6 , Hendrik P N Scholl  7   8 , Zisis Gatzioufas  9
Affiliations
Review

Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment

Panagiotis Georgoudis et al. Ophthalmol Ther. 2019 Mar.

Abstract

Mucous membrane pemphigoid (MMP) is a systemic cicatrizing autoimmune disease that primarily affects orificial mucous membranes, such as the conjunctiva, the nasal cavity, the oropharynx, and the genitalia. Ocular involvement occurs in about 70% of all MMP cases. Ocular MMP (OcMMP) also encompasses the conditions linear immunoglobulin A disease, mucosal dominated epidermolysis bullosa acquisita, and anti-laminin 332/anti-epiligrin/anti-laminin 5 pemphigoid. It is a complex clinical entity that may lead to ocular surface failure and result in inflammatory and infectious complications, as well as potentially devastating visual loss. Early diagnosis and appropriate treatment are of paramount importance and require a high level of expertise as this condition can be extremely challenging to diagnose and treat even for experienced clinicians. In this review we provide an up-to-date insight on the pathophysiology of OcMMP, with an emphasis on the current state of its diagnostics and therapeutics. Our the aim is to increase our understanding of OcMMP and highlight modern diagnostic and therapeutic options.

Keywords: Diagnostics; Mucous; Ocular pemphigoid; Pathophysiology; Treatment.

PubMed Disclaimer

References

    1. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115(2):253–261. - PubMed
    1. Williams GP, Radford C, Nightingale P, Dart JK, Rauz S. Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. Eye. 2011;25(9):1207–1218. - PMC - PubMed
    1. Hardy KM, Perry HO, Pingree GC, Kirby TJ., Jr Benign mucous membrane pemphigoid. Arch Dermatol. 1971;104(5):467–475. - PubMed
    1. Dart JK. The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on. Eye. 2017;31(2):301–332. - PMC - PubMed
    1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–379. - PubMed

LinkOut - more resources